$56MSeries C, 15 April 2026
Series C funds a Phase 2 trial of STC-15 in sarcoma, with the first patient dosed.
- Amount
- $56M
- Stage
- Series C
- Announced
- 15 April 2026
- Lead
- M Ventures
- Other investors
- Pfizer Ventures, Taiho Ventures, IP Group, UTokyo IPC, Fast Track Initiative
- Use of funds
- Series C funds a Phase 2 trial of STC-15 in sarcoma, with the first patient dosed.
- Checked
- Amount and date matched across 3 press sources
- Sources
- STORM Therapeutics raises $56M Series C axios.com
STORM Therapeutics raises $56M Series C ventureburn.com
STORM Therapeutics raises $56M Series C pulse2.com